TD Cowen Downgrades Thorne HealthTech to Market Perform, Raises Price Target to $10.2
Portfolio Pulse from richadhand@benzinga.com
TD Cowen analyst Oliver Chen has downgraded Thorne HealthTech (NASDAQ:THRN) from Outperform to Market Perform, while raising the price target from $8 to $10.2.
August 30, 2023 | 8:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Thorne HealthTech's rating has been downgraded to Market Perform by TD Cowen, but the price target has been raised to $10.2.
The downgrade to Market Perform suggests that the analyst believes the stock will perform similarly to other stocks in the market, indicating a neutral outlook. However, the increase in price target from $8 to $10.2 suggests a positive outlook on the stock's future price. The net effect on the stock's price in the short term is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100